AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China

$1.2bn Validation Of Chinese Capabilities

 
• By Brian Yang
  
arrow pointing to the year 2024 on a raised metal dial
AstraZeneca acquires Gracell Bio in validation of China cell therapy innovation • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia